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REVIEW
Abstract: The pathogenesis of ST-elevation myocardial infarction (STEMI) involves plaque
disruption, platelet aggregation and intracoronary artery thrombus formation. Aspirin is the
cornerstone of antiplatelet therapy in patients with STEMI, reducing the risk of recurrent
myocardial infarction or death during the acute phase and long term by about one-quarter.
Recent large randomized trials have demonstrated that the addition of clopidogrel to aspirin
reduces the risk of major ischemic events by up to a further one-third in patients with STEMI
treated with fibrinolytic therapy and undergoing percutaneous coronary intervention, with no
significant increase in bleeding. Thus, dual antiplatelet therapy with the combination of
clopidogrel and aspirin is becoming the new standard of care for the management of patients
with STEMI.
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Introduction
In the USA, approximately 865 000 people will suffer an acute ST-segment elevation
myocardial infarction (STEMI) per year (America Heart Association 2006). Most
cases of STEMI are a result of ruptured atherothrombotic plaque leading to thrombotic
occlusion of a coronary artery. Timely restoration of coronary blood flow with
fibrinolytic therapy (Rentrop et al 1979) or percutaneous coronary intervention
salvages myocardium, reduces infarct size, and prolongs survival (DeWood et al
1980; Keeley et al 2003).
Platelets play a pivotal role in the pathogenesis of acute coronary artery thrombosis.
Spontaneous atherosclerotic plaque rupture or mechanical plaque disruption during
catheterization of an atheromatous coronary artery exposes subendothelial proteins
to the circulating blood which leads to platelet adhesion, activation, and aggregation.
Release of tissue factor activates the coagulation system and leads to thrombin
generation. Thrombin converts fibrinogen to fibrin and further activates platelet,
leading to the recruitment of additional platelets to the site of vascular injury. Activated
platelets provide a phospholipid surface for the assembly of pro-coagulant clotting
factors. The resulting intracoronary thrombus can obstruct blood flow, causing
myocardial ischemia and the clinical manifestations of STEMI.
The benefits of antiplatelet drugs in patients with STEMI were first conclusively
demonstrated in the Second International Study of Infarct Survival (ISIS-2) trial
which randomized 17 187 patients presenting within 24 hours of onset of suspected
STEMI to intravenous streptokinase, aspirin 162.5 mg/day for 30 days, both, or neither
(ISIS-2 1988). At the end of 5 weeks, aspirin reduced the risk of vascular death by
23% and non-fatal myocardial infarction or stroke by 49% and 46%, respectively,
with no increase in major or intracranial bleeding. Despite the use of aspirin and
thrombolysis; however, 20% of STEMI patients did not obtain reperfusion of the
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infarct-related artery, and an additional 4%–6% of patients
developed re-occlusion of the infarct-related artery during
the index hospitalization (Dalen et al 1988, Fibrinolytic
Therapy Trialists’ [FTT] Collaborative Group 1994).
Furthermore, as many as 10% of patients with acute coronary
syndromes (ACS) who are treated with long-term aspirin
experience myocardial infarction, stroke, or death during
the next 2–3 years (Antithrombotic Trialists’ Collaboration
2002) These data suggest that more intensive antiplatelet
therapy may be required.
Clopidogrel (Plavix
®, Sanofi-Aventis, Paris France) is
an oral antiplatelet drug of thienopyridine class. An active
metabolite of clopidogrel irreversibly inhibits platelet
activation and aggregation by blocking the P2Y12 adenosine
diphosphate (ADP) receptor (Quinn and Fitzgerald 1999;
Patrono et al 2001). In patients with non-ST elevation ACS
and those undergoing percutaneous coronary intervention
(PCI), the combination of clopidogrel and aspirin reduces
the risk of recurrent myocardial infarction (MI) or death by
20%–30% (Mehta et al 2001; Yusuf et al 2001; Steinhubl et
al 2002). Dual antiplatelet therapy with the combination of
clopidogrel and aspirin has recently also been evaluated in
patients with STEMI. This review will discuss the role of
clopidogrel in STEMI patients treated medically (no PCI),
undergoing PCI, and undergoing coronary artery bypass
surgery.
STEMI patients treated medically
(no PCI)
Given the complementary antiplatelet effects of aspirin and
clopidogrel among patients with non ST-elevation
myocardial infarction (Yusuf et al 2001) it was hypothesized
that clopidogrel on a background of standard care (including
aspirin and fibrinolytic therapy) would prevent re-occlusion,
enhance infarct-related artery patency, and improve clinical
outcomes in patients with acute STEMI. Two large
randomized trials have compared the combination of
clopidogrel and aspirin with aspirin alone as an adjunct to
standard therapy in patients with STEMI (Chen et al 2005;
Sabatine et al 2005a).
The CLopidogrel as Adjunctive ReperfusIon TherapY
(CLARITY) – Thrombosis In Myocardial Infarction (TIMI)
28 Trial was a randomized, double-blind, trial comparing
clopidogrel with placebo in 3491 patients aged 18–75 years
who presented within 12 hours of onset of symptoms of
STEMI (Sabatine et al 2005a). Patients were randomized
to receive a 300-mg loading dose of clopidogrel followed
by 75 mg once-daily or placebo. More than 99% of patients
also received fibrinolytic therapy. Study treatment was
continued until the time of angiography (2–8 days after
randomization) or hospital discharge (maximum of 8 days)
if angiography was not performed. Open-label clopidogrel
therapy was continued post-angiography at the discretion
of the treating physician. All patients also received aspirin,
heparin (either unfractionated heparin [UFH] or low-
molecular-weight heparin [LMWH]), and a fibrinolytic
agent.
The incidence of the primary outcome, a composite of
occlusion of infarct-related artery on angiography, or death
or MI prior to angiography, was significantly reduced
among patients receiving clopidogrel compared with
placebo (15.0% clopidogrel vs 21.7% placebo, odds
reduction 36%; 95% CI: 24%-47%; p<0.001), and a
consistent treatment effect was evident across all subgroups
of patients (Figure 1) (Sabatine et al 2005a). Clopidogrel
had the greatest effect on reducing the rate of an occluded
infarct-related artery (18.4% placebo vs 11.7% clopidogrel;
41% odds reduction; 95% CI: 0.28–0.52; p<0.001) and there
was a consistent reduction in recurrent MI (3.6% placebo
vs 2.5% clopidogrel; 30% odds reduction; p=0.08) but no
reduction in death (2.2 placebo vs 2.6% clopidogrel;
p=0.49).
At 30 days, clopidogrel significantly reduced the odds
of the composite outcome of cardiovascular death, recurrent
MI, or recurrent ischemia leading to urgent revascularization
by 20%: 0.80 (95% CI: 0.65–0.97; p=0.03). There also was
a statistically significant 31% reduction in the odds of
recurrent MI in the clopidogrel group compared with placebo
but there was no difference in the rate of cardiovascular
death, and a non-significant 24% reduction in the odds of
recurrent myocardial ischemia leading to need for urgent
revascularization (4.5% placebo vs 3.5% clopidogrel;
p=0.11)
The incidence of TIMI major and minor bleeding was
similar in the clopidogrel and placebo groups (major
bleeding: 1.3% clopidogrel vs 1.1% placebo; p=0.64; and
minor bleeding: 1.0% clopidogrel vs 0.5% placebo; p=0.17).
There was no significant difference in the incidence of
intracranial hemorrhage between the two randomized
treatment groups (0.5% clopidogrel vs 0.7% placebo;
p=0.38).
The Clopidogrel and Metoprolol in Myocardial
Infarction Trial (COMMIT) randomized 45852 patients
presenting within 24 hours of onset of symptoms of
suspected MI to receive clopidogrel versus placebo and
metoprolol versus placebo using a 2 x 2 factorial designVascular Health and Risk Management 2006:2(4) 381
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(Chen et al 2005). Patients received aspirin 162 mg daily
and were randomized to clopidogrel 75  mg daily (no loading
dose) or placebo. 55% of patients received fibrinolytic
therapy, which was administered prior to randomization in
the majority of cases. Study treatments were continued until
hospital discharge or for 28 days and the co-primary
outcomes were death and the composite of death, recurrent
MI, or stroke.
Among the broad range of acute STEMI patients
randomized in the COMMIT study (ECG changes: ST-
segment elevation or left bundle block branch) clopidogrel
reduced the relative risk of death by 7% compared with
placebo (7.5% clopidogrel vs 8.1% placebo; 95% CI: 0.01–
0.13; p=0.03) (Figure 2) and reduced the relative risk of the
composite outcome of death, recurrent MI or stroke by 9%
(9.2% clopidogrel vs 10.1% placebo; 95% CI: 0.03–0.14;
p=0.002) (Figure 3). The results were consistent in patients
Figure 1 Death, myocardial infarction or occlusion of infarct-related artery on angiography in the CLARITY randomized trial. Reproduced from Sabatine MS, Cannon
CP, Gibson CM, et al. 2005a. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med, 352:1179-89.
Copyright © 2005 Massachusetts Medical Society.
Number of Odds Event rates (%) 
Characteristic  patients reduction Clopidogrel Placebo 
OVERALL  3491 36 15.0 21.7
Age 
<65 years 2466 42 13.2 21.0
t65 years 1015 22 19.0 23.1
Gender 
Male 2796 35 14.5 20.8
Female  685 38 16.9 24.7
Infarct location 
Anterior  1416 33 15.0 20.7
Non -  anterior  2065 38 15.0 22.2
Fibrinolytic 
Fibrin -  specific  2397 31 14.7 20.1
Non -  fibrin specific  1084 44 15.7 24.9
Predominant heparin 
LMWH  1429 31 11.4 15.7
UFH  1431 42 17.8 27.1
None  621 26 17.1 21.9
1.0 0.4 0.6 0.8 1.2 1.6
Clopidogrel better Placebo better
Figure 2 Effect of clopidogrel on death before first discharge from hospital in
COMMIT. Reproduced from Chen ZM, Jiang LX, Chen YP, et al. 2005. Addition of
clopidogrel to aspirin in 45,852 patients with acute myocardial
infarction:randomised placebo-controlled trial. Lancet, 366:1607-21. Copyright ©
2005, with permission from Elsevier.
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Figure 3 Effects of clopidogrel on primary end point, a composite of death,
reinfarction, or stroke before first discharge from hospital in COMMIT
Reproduced from Chen ZM, Jiang LX, Chen YP, et al. 2005. Addition of
clopidogrel to aspirin in 45,852 patients with acute myocardial
infarction:randomised placebo-controlled trial. Lancet, 366:1607-21. Copyright ©
2005, with permission from Elsevier.
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treated with fibrinolytic therapy compared with those who
did not receive fibrinolytic therapy. Clopidogrel also reduced
the risk of non-fatal MI (1.2% clopidogrel vs 1.4% placebo;
p=0.01), but did not reduce the risk of non-fatal stroke (0.6%
clopidogrel vs 0.6% placebo; p=0.33). There was no
difference in the combined incidence of ischemic and
hemorrhagic strokes among patients treated with clopidogrel
compared with placebo (0.9% clopidogrel vs 1.1% placebo;
p=0.11).
Clopidogrel compared with placebo did not increase the
risk of major non-cerebral bleeding (fatal and transfused)
and cerebral bleeding (0.58% clopidogrel vs 0.55% placebo;
p=0.59) and did not increase fatal cerebral bleeding (0.17%
vs 0.18%; p=NS) or non-fatal cerebral bleeding (0.07%
clopidogrel vs 0.07% placebo).
Comparing CLARITY and COMMIT
trials
The major differences between the CLARITY and COMMIT
trials are summarized in Table 1. The CLARITY trial
(Sabatine et al 2005a) did not include patients older than 75
years or patients presenting more than 12 hours after
symptom onset. All patients received a 300-mg loading dose
of clopidogrel and the duration of exposure to study drug
was 2–3 days (median 4 doses). Almost all patients received
fibrinolysis (slightly more than one-half of the patients
subsequently underwent PCI), and patency of the infarct-
related artery was included as a component of the primary
efficacy outcome. By contrast, the COMMIT trial (Chen et
al 2005) did not have an upper age limit (26% were aged
greater than 70 years), also included patients between 12
and 24 hours after onset of symptoms, and did not administer
a loading dose of clopidogrel. Study drug was continued
for 2–3 weeks (mean 14.9 days), one-half of patients did
not receive fibrinolysis, and only 3% of patients
subsequently underwent PCI.
The results of the CLARITY and COMMIT studies are
complementary. The CLARITY study demonstrated that the
addition of clopidogrel to aspirin in patients with STEMI
improved coronary perfusion and the COMMIT study
demonstrated improvements in clinical outcomes, with a
reduction in both death and recurrent ischemic events among
patients randomized to clopidogrel. Clopidogrel did not
increase major bleeding or intracranial hemorrhage, despite
the use of a loading dose in CLARITY and the inclusion of
patients aged greater than 75 years in COMMIT.
Based on the results of COMMIT and CLARITY, for
every one thousand patients with STEMI treated in hospital
for about 2–3 weeks, the addition of clopidogrel to standard
care, including aspirin, saves 50 lives and prevents another
50 major cardiovascular events.
STEMI patients undergoing PCI
Efficacy of clopidogrel in PCI
Early trials demonstrated the efficacy of ticlopidine plus
aspirin compared with aspirin plus anticoagulation to
prevent stent thrombosis in patients undergoing PCI (Berger
et al 1998; Bertrand et al 1998; Leon et al 1998; Urban et al
1998; Smith et al 2001). The Clopidogrel Aspirin Stent
International Cooperative Study (CLASSICS) suggested that
clopidogrel was as effective as ticlopidine to prevent
ischemic complications in patients undergoing PCI
(Bertrand et al 2000) and clopidogrel subsequently replaced
ticlopidine for this indication because, unlike ticlopidine, it
does not cause potentially fatal neutropenia. The PCI
substudy of the Clopidogrel in Unstable Angina to prevent
Recurrent Ischemic Events (CURE) trial demonstrated that
pre-treatment with clopidogrel (median duration of pre-
treatment of 10 days) compared with placebo was associated
with a 30% reduction in myocardial infarction, stroke, or
cardiovascular death at 30 days (RR 0.70; 95% CI: 0.50–
0.97, p=0.03) and a continuing benefit out to 1 year (RR
0.72; 95% CI: 0.52–0.96) (Mehta et al 2001). The
Clopidogrel for the Reduction of Events During Observation
(CREDO) trial provided additional supporting evidence of
a benefit of clopidogrel pre-treatment in patients undergoing
PCI (Steinhubl et al 2002). Analysis by duration of pre-
treatment demonstrated that patients who received
clopidogrel at least 6 hours before PCI had a 38.6%
reduction in the risk events which was borderline statistically
significant (p=0.051).
Table 1 Comparison of the CLARITY and COMMIT
randomized clinical trials (Chen et al 2005; Sabatine et al
2005a)
Characteristic COMMIT  CLARITY
Patients (n)  45852 3491
Outcome  Death/MI/stroke Infarct patency 
Symptom onset, hours  <24 <12
Age, years Up to 100 Up to 75 
Loading dose given  No  Yes
Thrombolysis  One-half of patients All patients
Duration clopidogrel, days 2–3 weeks 2–3 days
Follow-up PCI  Very few patients  Two thirds
Abbreviations: PCI, percutaneous coronary intervention.Vascular Health and Risk Management 2006:2(4) 383
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STEMI patients undergoing primary PCI
There are no randomized trials that have specifically
evaluated the use of combined clopidogrel and aspirin in
patients with STEMI undergoing primary PCI.
STEMI patients undergoing PCI after
initial medical therapy
The PCI-CLARITY study was a prospectively planned
analysis of the 1863 patients undergoing PCI after mandated
angiography in the CLARITY trial (Sabatine et al 2005b).
Pre-treatment with clopidogrel for an average of 3 days prior
to PCI significantly reduced the incidence of cardiovascular
death, MI, or stroke (3.6% clopidogrel vs 6.2% placebo;
adjusted OR 0.54, 95% CI: 0.35–0.85; p=0.008). Pre-
treatment with clopidogrel also reduced the incidence of
MI or stroke prior to PCI (4.0% clopidogrel vs 6.2% placebo;
OR, 0.62, 95% CI: 0.40–0.95; p=0.03). Overall, pre-
treatment with clopidogrel resulted in a highly significant
reduction in cardiovascular death, MI, or stroke from
randomization through 30 days (7.5% clopidogrel vs 12.0%
placebo; adjusted OR, 0.59, 95% CI: 0.43–0.81; p=0.001;
number needed to treat = 23). There was no significant
excess in the rates of TIMI major or minor bleeding (2.0%
clopidogrel vs 1.9% placebo; p=0.99). These data add further
support to the early use of clopidogrel in STEMI and the
strategy of routine clopidogrel pre-treatment in patients
undergoing PCI.
A pooled analysis of the results of PCI-CLARITY, PCI-
CURE, and CREDO trials by Sabatine and colleagues
demonstrated a significant reduction in the risk of
cardiovascular events before and after PCI suggesting that
clopidogrel pre-treatment should be started as soon as
possible in patients undergoing PCI, including patients
presenting with STEMI (Sabatine et al 2005b).
STEMI patients undergoing
coronary artery bypass graft
(CABG) surgery
There are limited randomized data regarding the role of
clopidogrel in patients undergoing CABG surgery and the
majority of the available data relate to non-STEMI patients.
In the CURE study, 2072 of 12 562 patients with non-ST-
elevation ACS underwent surgical revascularization during
the trial (Fox et al 2004). The median time from
randomization to CABG in the overall trial was 26 days
and among patients undergoing CABG during initial
hospitalization was 12 days. Compared with aspirin alone,
clopidogrel combined with aspirin was associated with a
19% reduction in the risk of cardiovascular death, MI, or
stroke among patients undergoing CABG surgery during
the initial hospitalization (13.4% clopidogrel vs 16.4%
placebo; RR 0.81, 95% CI: 0.59–1.12), and an 11% relative
risk reduction among patients who underwent CABG at any
time during the 9-month treatment period (14.5%
clopidogrel vs 16.2% placebo; RR 0.89, 95% CI: 0.71–1.11).
The benefits of clopidogrel were seen mainly in the pre-
operative period (RR 0.82; 95% CI: 0.58–1.16) and less so
in the post-operative period (RR 0.97; 95% CI: 0.74–1.26).
However, the post-operative data need to be interpreted with
caution because clopidogrel was withheld for a median of
10 days after surgery, and was restarted in only 75% of those
who stopped the drug before surgery.
Observational studies suggest that pre-operative
exposure to clopidogrel and aspirin in patients undergoing
CABG surgery increases the risk of post-operative bleeding.
In a prospective observational study involving 312
consecutive patients requiring urgent or emergent CABG
surgery, Chu and colleagues reported that clopidogrel use
within 4 days of surgery was an independent risk factor for
increased transfusion requirements (OR 4.22, 95% CI: 20.7–
9.34; p=0.001) and was associated with increased blood loss
and reoperation due to bleeding (Chu et al 2004). Yende
and colleagues reported an increase in transfusion
requirements (72.6% clopidogrel vs 51.6% no clopidogrel,
p=0.007) and re-operation rates (9.8% vs 1.6%, p=0.01)
among 247 patients who had received clopidogrel and
aspirin within 5 days of surgical revascularization compared
with those who did not (Yende and Wunderink 2001). Hongo
and colleagues reported a statistically significant increase
in 24 hour chest tube blood loss and transfusion requirements
and a tenfold increase in re-operation for bleeding (0.6%
no clopidogrel vs 6.8% clopidogrel, p=0.018) among 224
patients who had received clopidogrel within 7 days of
surgery compared with those who did not (Hongo et al
2002).
Information regarding the bleeding risk of clopidogrel
in CABG surgery is also available from randomized trials.
In a subgroup analysis of 912 patients who had stopped
clopidogrel less than 5 days before CABG surgery in the
CURE trial (Yusuf et al 2001) there was increased risk of
minor bleeding (5.1% clopidogrel vs 2.4% placebo,
p<0.001) and a trend towards an increased risk of major
bleeding (9.6% clopidogrel vs 6.3% placebo, p=0.06) among
patients in the clopidogrel group compared with placebo.Vascular Health and Risk Management 2006:2(4) 384
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In contrast, there was no excess of major bleeding after
CABG surgery among patients who discontinued
clopidogrel at least 5 days prior to surgery (4.4% clopidogrel
vs 5.3% placebo; p=0.53).
In the CREDO trial (Leon et al 1998), three-quarters of
all major bleeds occurred in patients undergoing CABG,
although there was no difference in bleeding risk between
treatment groups (68% clopidogrel vs 78% placebo).
In the CLARITY trial, pre-treatment with clopidogrel
did not lead to a significant increase in major bleeding at 30
days among 136 patients who underwent CABG during the
initial hospitalization (7.5% clopidogrel vs 7.2% placebo;
p=1.00), including those who had CABG within 5 days of
cessation of clopidogrel (9.1% clopidogrel vs 7.9% placebo;
p=1.00) (Urban et al 1998).
Taken together, these data suggest that caution should
be exercised when prescribing clopidogrel to those in whom
CABG surgery is likely to be performed within 5–7 days,
balancing the risk of recurrent cardiac ischemia and the risk
of post-operative bleeding and its consequences (Levine et
al 2003).
Cannon and colleagues recently reviewed the literature
evaluating the benefits and risks of oral antiplatelet therapy
among patients undergoing CABG surgery and proposed
the following approach: For patients undergoing elective
CABG, clopidogrel should be withdrawn 5 days prior to
surgery. Among high-risk patients requiring urgent CABG,
if safe to do so, surgery should be scheduled in 3–5 days
while withholding clopidogrel. If not, proceed to surgery
on a background of antiplatelet therapy with the aim of
reducing the pre-operative risk of MI, and intervene with
early platelet transfusion and aprotinin and tranexamic acid
if bleeding occurs (Cannon et al 2005).
Other unresolved issues associated
with clopidogrel in STEMI
Need for a loading dose of clopidogrel
and possible effect of loading dose on
bleeding
The CLARITY and COMMIT studies do not clarify whether
a loading dose of clopidogrel (300 mg) compared with no
loading dose confers additional benefit or if it increases the
risk of bleeding in elderly patients. An initial loading dose
of clopidogrel achieves more rapid and complete platelet
inhibition but, even without its use, there was already a
separation of the time-to-event curves during the first 12
hours in the COMMIT study, and there was a significant
reduction in death by the end of day one (11%, 99% CI:
0%–20%; p=0.01). The benefits of clopidogrel administered
without a loading dose are achieved without an excess of
major bleeding, even in the those aged greater than 70 years
(n=11934). In the younger STEMI patient population (mean
age 57 years) in the CLARITY trial, the use of a loading
dose of clopidogrel of 300mg followed by 75 mg daily for
2–3 days did not increase bleeding. These data indicate that
a loading dose of clopidogrel can be safely administered in
STEMI patients aged less than 75 years and that clopidogrel
is effective in those aged greater than 70 years even without
a loading dose.
Optimal duration of combined
antiplatelet therapy in patients with
STEMI
There are no randomized trials assessing the long-term (>28
days) effect of clopidogrel in patients with STEMI. A benefit
of extended duration treatment with clopidogrel has,
however, been suggested in patients with unstable coronary
artery disease without STEMI and in patients undergoing
PCI. In the CURE study involving 12 562 aspirin-treated
patients with non-ST elevation acute coronary syndrome,
the combination of clopidogrel administered as a 300-mg
loading dose followed by 75 mg/day for 3–12 months was
superior to placebo in preventing the primary composite
outcome of stroke, MI, and vascular death (RR 0.80; 95%
CI: 0.72–0.90, p<0.001) (Yusuf et al 2001). The benefits of
clopidogrel emerged within the first 24 hours of
commencing treatment and continued to accrue throughout
the duration of the study.
The CREDO study examined the effect of long-term (12
months) treatment with clopidogrel in patients undergoing
elective PCI (Steinhubl et al 2002). All patients received
clopidogrel for the first 28 days after PCI but thereafter
patients who had received pre-treatment with clopidogrel
continued treatment with clopidogrel 75 mg/day while those
who received pre-treatment placebo continued treatment
with placebo. At 1 year, clopidogrel compared with placebo
was associated with a 26.9% (95% CI: 3.9%–44.4%;
p=0.02) reduction in the primary composite outcome of MI,
stroke, and cardiovascular death. A subgroup analysis
demonstrated that continued treatment with clopidogrel
beyond 28 days was associated with a further 37.4% relative
risk reduction in the composite outcome of MI, stroke, andVascular Health and Risk Management 2006:2(4) 385
Clopidogrel for treatment of STEMI
cardiovascular death (95% CI: 1.8%–60.1%, p=0.04). There
was a no significant increase in the risk of bleeding at 1
year (8.8% clopidogrel and aspirin vs 6.7% aspirin alone,
p=0.07) (Steinhubl et al 2002).
Stent thrombosis following PCI is a serious
complication, associated with a 30-day mortality rate of
approximately 10% (Cutlip et al 2001). Refinement in stent
deployment techniques in combination with dual antiplatelet
therapy (aspirin and thienopyridine) have reduced the
incidence of stent thrombosis to approximately 1% (Leon
et al 1998; Bertrand et al 2000; Muller et al 2000; Cutlip et
al 2001). The combination of clopidogrel 75 mg/day with
or without a loading dose of 300 mg started post procedure
and continued for 4 weeks among patients receiving bare-
metal (non-drug-eluting) stents is highly effective in
reducing the rate of thrombotic stent occlusion with no
significant increase the rate of bleeding (Bertrand et al 2000;
Muller et al 2000).
Drug-eluting stents containing sirolimus (Cordis, Miami
Lakes, FL, USA) or paclitaxel (Boston Scientific, Natick,
MA, USA) markedly reduce neo-intimal hyperplasia and
subsequent restenosis (Sousa et al 2001; Morice et al 2002;
Park et al 2003) especially among patients with risk factors
for restenosis, such as diabetes mellitus, small-vessel
disease, and long-lesion lengths. Because of the concern
that late stent thrombosis may occur in such patients, most
randomized clinical trials comparing the efficacy and safety
of drug-eluting and bare-metal stents extended combined
clopidogrel and aspirin treatment to 3–6 months in those
who received a drug-eluting stent (Moses et al 2003; Park
et al 2003; Holmes et al 2004; Stone et al 2004a, 2004b).
However, the occurrence of stent thrombosis after
discontinuation of clopidogrel at 6 months in 1% of patients
who have received a drug-eluting stent has prompted some
clinicians to recommend long-term or indefinite clopidogrel
in these patients.
Taken together, the data indicate that clopidogrel should
be continued for up to 1 month in patients with STEMI, for
at least 1 month after PCI involving a bare metal stent, and
for at least 3–6 months after PCI involving a drug-eluting
stent. There is no direct evidence for continuing clopidogrel
beyond 1 month in patients with STEMI or beyond 3–6
months in those undergoing PCI with a drug-eluting stent
but indirect evidence from trials of patients with unstable
coronary artery disease suggests that clopidogrel may be
beneficial in these patients if continued long term.
Suboptimal response to
clopidogrel (clopidogrel
“resistance”)
Recent demonstration of variability in the antiplatelet
response of clopidogrel has evoked the concept of
clopidogrel resistance. However, a standardized definition
and laboratory approach to the measurement of the
antiplatelet effect of clopidogrel has not been established,
and there is uncertainty concerning the prognostic
importance of suboptimal antiplatelet response to
clopidogrel in STEMI patients. Matetzky and colleagues
divided 60 patients with STEMI undergoing primary PCI
in quartiles based on the percent inhibition of ADP-induced
platelet aggregation at day 6 compared with baseline
(Matetzky et al 2004). All patients received a loading dose
of clopidogrel of 300 mg followed by a maintenance dose
of 75 mg/day. Six of the 15 patients in the first (lower)
quartile of percent inhibition of ADP-induced platelet
aggregation developed a recurrent vascular event (STEMI,
subacute stent thrombosis, acute coronary syndrome, or
peripheral arterial occlusion) during 6 months of follow up
compared with only 1 of 15 patients in the second quartile
and none in the third and fourth (upper) quartiles. Before
any firm conclusions can be made about the clinical
relevance of suboptimal antiplatelet response to clopidogrel,
the results need to be reproduced in larger prospective
studies.
There is evolving evidence that higher doses of
clopidogrel improve laboratory response. Among patients
undergoing elective PCI, several observational studies have
reported that a loading dose of clopidogrel of 600 mg is
associated with greater platelet function inhibition compared
with a 300-mg loading dose (Angiolillo et al 2004; Gurbel
et al 2005). The Antiplatelet therapy for Reduction of
Myocardial Damage during Angioplasty (ARMYDA-2)
Study reported that compared with a loading dose of
clopidogrel of 300 mg, pretreatment with a 600-mg loading
dose of clopidogrel 4–8 hours before elective PCI
significantly reduces the primary outcome at 30 days, a
composite of death, MI, or target vessel revascularization
(12% vs 4%; p=0.041) and 50% risk reduction of MI (OR
0.48; 95% CI: 0.15–0.97; p=0.044) (Patti et al 2005). The
size of the treatment effect of the 600-mg loading dose of
clopidogrel observed in ARMYDA-2 is, however,
implausibly large and requires confirmation. There is noVascular Health and Risk Management 2006:2(4) 386
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evidence that a higher dose of clopidogrel improves clinical
outcome among STEMI patients.
Guidelines for antiplatelet therapy
in ST -segment elevation
myocardial infarction
The American College of Cardiology/American Heart
Association (ACC/AHA) Guidelines for the Management
of Patients with STEMI 2004
 recommend aspirin 160–
325 mg/day given on day 1 of acute myocardial infarction
and continued indefinitely thereafter in all patients using a
dose of 75–162 mg/day (Antman et al 2004). In light of the
results of the COMMIT (no loading dose of clopidogrel
given) and CLARITY (loading dose of clopidogrel in
STEMI patients <75 years) trials, it seems reasonable to
add clopidogrel to aspirin in patients presenting with STEMI
as an adjunct to fibrinolytic therapy (Chen et al 2005;
Sabatine et al 2005a). The safety of using a loading dose of
clopidogrel of 300 mg in STEMI patients aged over 70 years
is unknown, and should be balanced against the risk of
bleeding. The US Food and Drug Administration recently
approved clopidogrel for use in patients with STEMI not
undergoing PCI based on the results of the COMMIT and
CLARITY studies (FDA 2006).
For STEMI patients undergoing primary PCI,
clopidogrel should be given as a loading dose of clopidogrel
of 300 mg followed by 75 mg daily. Treatment should be
continued for at least 1 month after bare metal stent
implantation and for at least 3–6 months after drug-eluting
stent implantation (3 months for sirolimus, 6 months for
paclitaxel). In patients who are not at high risk for bleeding,
it is reasonable to continue clopidogrel for 12 months or
more to prevent late stent thrombosis (Antman et al 2004;
Smith et al 2006). For STEMI patients taking clopidogrel
in whom CABG is planned, the drug should be withheld
for at least 5 days and preferably for 7 days unless the
urgency for revascularization outweighs the risks of
bleeding.
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